Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2008 Aug 1;26(22):3791-6.
doi: 10.1200/JCO.2008.16.1711.

Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense?

Affiliations
Review

Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense?

Lori E Dodd et al. J Clin Oncol. .

Erratum in

  • J Clin Oncol. 2009 Apr 20;27(12):2109-10

Abstract

Progression-free survival is an important end point in advanced disease settings. Blinded independent central review (BICR) of progression in randomized clinical trials has been advocated to control bias that might result from errors in progression assessments. However, although BICR lessens some potential biases, it does not remove all biases from evaluations of treatment effectiveness. In fact, as typically conducted, BICRs may introduce bias because of informative censoring, which results from having to censor unconfirmed locally determined progressions. In this article, we discuss the rationale for BICR and different ways of implementing independent review. We discuss the limitations of these approaches and review published trials that report implementing BICR. We demonstrate the existence of informative censoring using data from a randomized phase II trial. We conclude that double-blinded trials with consistent application of measurement criteria are the best means of ensuring unbiased trial results. When such designs are not practical, BICR is not recommended as a general strategy for reducing bias. However, BICR may be useful as an auditing tool to assess the reliability of marginally positive results.

PubMed Disclaimer

Figures

Fig 1.
Fig 1.
(A) Demonstrates the existence of informative censoring via conditional progression-free survival (PFS) curves. The PFS curves are conditional on time of local progression. The “observed curve” plots the centrally determined progression from the time of investigator-assessed progression for the 16 patients for whom investigator-assessed progression was called before the blinded independent central review (BICR) –determined time. The “expected curve without informative censoring” is the curve that would be expected if the censoring was not informative. Curves are constructed as described in the Appendix. Data are from Yang et al. (B) Demonstrates the impact of informative censoring shown in 1A on the unconditional PFS curves. The curves plot BICR PFS with and without informative censoring. However, the “with informative censoring” curve censors cases for which BICR progression determined after local progression at the locally designated progression time.

Comment in

References

    1. Johnson JR, Williams G, Pazdur R: End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 21:1404-1411, 2003 - PubMed
    1. Freidlin B, Korn EL, Hunsberger S, et al: Proposal for the use of progression-free survival in unblinded randomized trials. J Clin Oncol 25:2122-2126, 2007 - PubMed
    1. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000 - PubMed
    1. Miller AB, Hoogstraten B, Staguet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981 - PubMed
    1. Juni P, Altman DG, Egger M: Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ 323:42-46, 2001 - PMC - PubMed

MeSH terms

Substances